Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

Randomized, Single Blind, Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets of PZQ and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

The primary objective of the trial is to compare the "overall palatability" of the new orally disintegrating L-Praziquantel (L-PZQ ODT), the new racemate PZQ ODT (Rac-PZQ ODT) and the current available racemate PZQ tablets (reference) as assessed by means of human gustatory sensation tests (100 millimeter [mm] visual analogue scale [VAS] scoring modified by the incorporation of a 5 point facial hedonic scale).

The secondary objectives are

• To obtain feedback from children regarding the taste of different formulations using an open ended questionnaire
• To document any discomfort or other observation in relation to acceptance of the study medication

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: L-PZQ ODT; Drug: Rac-PZQ ODT; Drug: L-PZQ ODT; Drug: Rac-PZQ ODT; Drug: Cesol®

Detailed Description

Initially pupils will be invited with their parents to school where they will be asked to give consent/assent in to the study and they will be instructed on how to follow up the taste study procedures. Enrollments will occur in the health facilities in Ikwiriri/Kibiti at the end of successive training. Informed consent from parents and guardians and assent from the child will be obtained before participation in the study. The study will be conducted in school children 6 years and older as recommended by the Committee for medical product for human use (CHMP) reflection paper: formulations of choice for the pediatric population.

-This is a randomized, five-period cross over, single center swill and spit taste study where the drug will not be swallowed but will be spit out after tasting.

On Day 1, the subjects will assess the palatability of the following arms in a randomized sequence:

• L-PZQ ODT (150 mg) put and disintegrated in the mouth
• Rac- PZQ ODT (150 mg) put and disintegrated in the mouth

On Day 2, the subjects will assess the palatability of the following arms in a randomized sequence:

• L-PZQ ODT (150 mg) dispersed in water administered in the mouth cavity
• Rac- ODT (150 mg) dispersed in water administered in the mouth cavity
• 150 mg current PZQ tablet (1/4 of a 600 mg tablet) crushed, dispersed in water and administered in the mouth cavity

Gustatory sensation studies will be performed on the different formulations immediately after tasting and 2-5 min after the study drug has been spat out.

All volunteers will be asked to place a mark along the line with the use of a 100 mm visual analogue scale (VAS) that incorporates a 5 points hedonic scale for "overall palatability".

In addition, any discomfort or other observation in relation to acceptance of the study medication (Example: spitting out of the medicine) will be reported by the parents or investigator.

An open ended questionnaire (description of mouth feeling and taste description) will be conducted for each child during the washout period. After the trial a therapeutic dose of Praziquantel will be made available to the local health council and management team to provide to the participating school.

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• Tanzania
  • Rufiji
    • Ikwiriri, Rufiji, Tanzania
      • Ifakara Health Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 11 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

1. Children male or female aged 6-11 years (inclusive)
2. Parents or guardians gave written informed consent prior to any trial related procedure and child gave assent
3. Able to communicate well with the Investigator, understanding the protocol requirements and restrictions, and willing to comply with the requirements of the entire trial
4. Subjects should be able to hold 2 milliliter (mL) of any appropriate juice in their mouth for 10 seconds without swallowing it and to keep a candy in the mouth for 20 seconds without swallowing it
5. Children who are able to properly assess and differentiate flavours of different soft drinks
6. Children who are able to use a hedonic scale (children were trained before the study)

Exclusion criteria:

1. Unlikely to comply with the protocol requirements, instructions and trial-related restrictions, example: uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial
2. Children with any condition or dietary habit known to interfere with the sense of smell and taste, ingestion of any medication (except paracetamol)
3. Children with significant illness in the previous 2 weeks
4. Any surgical or medical condition, or any significant disease that in the opinion of the investigator, constitutes a risk or a contraindication for the participation of the subject in the study that could interfere with the study objectives, conduct or evaluation
5. Children who have participated in any clinical investigation within the previous 4 weeks

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Period 1 and 2; A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue	Drug: L-PZQ ODT; L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water; Other Names: MSC 2499550A; Drug: Rac-PZQ ODT; Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water; Other Names: MSC1028703; Drug: L-PZQ ODT; L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water; Other Names: MSC 2499550A; Drug: Rac-PZQ ODT; Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water; Other Names: MSC1028703A
Experimental: Period 3, 4 and 5; C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water	Drug: L-PZQ ODT; L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water; Other Names: MSC 2499550A; Drug: Rac-PZQ ODT; Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water; Other Names: MSC1028703; Drug: L-PZQ ODT; L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water; Other Names: MSC 2499550A; Drug: Rac-PZQ ODT; Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water; Other Names: MSC1028703A; Drug: Cesol®; Cesol® tablet at a dose of 150 mg crushed in water; Other Names: PZQ

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Palatability Visual Analogue Scale (VAS) Score at 0 Minute (Right After the Spit-out of the Investigational Medicinal Product [IMP])	Overall palatability was assessed on a 0 to 100 unit VAS scale, where higher scores indicate better palatability.	0 minute (Right After the Spit-out of the IMP)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Palatability VAS Score at 2-5 Minutes	Overall palatability was assessed on a 0 to 100 unit VAS scale, where higher scores indicate better palatability.	2-5 minutes (After the IMP has been spat out)
Number of Subjects With Mouth Feeling and Taste Description Evaluation	Mouth feeling was described in terms of "sweet", "bitter", "sticky" or "smooth" as per the experience of the subject with the trial medication.	2-5 minutes (After the IMP has been spat out)
Number of Subjects With Discomfort or Observations Relating to Acceptance of the Study Medication		2-5 minutes

Collaborators and Investigators

• Sponsor: Merck KGaA, Darmstadt, Germany
• Collaborators: Swiss Tropical & Public Health Institute

Publications and helpful links

General Publications

• CHMP. (2005). Reflection paper: formulation of choice for the paediatric population. EMA
• Mahende MK, Huber E, Kourany-Lefoll E, Ali A, Hayward B, Bezuidenhout D, Bagchus W, Kabanywanyi AM. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021 Jun 9;15(6):e0007370. doi: 10.1371/journal.pntd.0007370. eCollection 2021 Jun.

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Actual): May 1, 2015
• Study Completion (Actual): May 1, 2015

Study Registration Dates

• First Submitted: December 9, 2014
• First Submitted That Met QC Criteria: December 10, 2014
• First Posted (Estimate): December 11, 2014

Study Record Updates

• Last Update Posted (Actual): March 6, 2017
• Last Update Submitted That Met QC Criteria: January 12, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: Healthy; L-PZQ; PZQ; MSC2499550A; Praziquantel
• Other Study ID Numbers: EMR200661-002